Skip to main content Skip to section navigation Skip to footer
Becton, Dickinson and Company - Corporate Home
  • Products
  • Solutions
    • Administrator
      • Ambulatory Surgery Center Solutions
      • BD Hypodermic Needle and Syringe Solutions
      • Diagnostic Accuracy and Efficiency
      • Hazardous Drug Safety
      • Integrated Diagnostic Solutions
      • Medication Management Solutions
      • Patient Safety Solutions
      • Sepsis Management
      • Surgical Solutions
      • Targeted Temperature Management
      • Vascular Access Management (VAM)
    • Clinician
      • Ambulatory Surgery Center Solutions
      • Antimicrobial Resistance
      • BD Original Equipment Manufacturing (OEM)
      • BD Hypodermic Needle and Syringe Solutions
      • Cervical Cancer Screening Portfolio
      • Clinical and Lab Support
      • Diagnostic Accuracy and Efficiency
      • Hazardous Drug Safety
      • Integrated Diagnostic Solutions
      • Medication Management Solutions
      • Patient Safety Solutions
      • Sepsis Management
      • Stone Management
      • Surgical Solutions
      • Targeted Temperature Management
      • Vascular Access Management (VAM)
    • Distributor
      • BD Original Equipment Manufacturing (OEM)
      • BD Hypodermic Needle and Syringe Solutions
    • Drug Development Company
      • Drug Delivery Systems
    • Medical Device Manufacturer
      • BD Original Equipment Manufacturing (OEM)
    • Laboratory
      • Antimicrobial Resistance
      • BD Original Equipment Manufacturing (OEM)
      • Cervical Cancer Screening Portfolio
      • Clinical and Lab Support
      • Clinical Microbiology
      • Diagnostic Accuracy and Efficiency
      • Integrated Diagnostic Solutions
      • Patient Safety Solutions
      • Pharmaceutical Microbiology
      • Sepsis Management
    • Pharmacy
      • BD Hypodermic Needle and Syringe Solutions
      • Hazardous Drug Safety
      • Integrated Diagnostic Solutions
      • Medication Management Solutions
      • Patient Safety Solutions
      • Pharmaceutical Microbiology
      • Sepsis Management
      • Vascular Access Management (VAM)
    • Surgery
      • Ambulatory Surgery Center Solutions
      • BD Hypodermic Needle and Syringe Solutions
      • Hernia Repair Solutions
      • Patient Safety Solutions
      • Plastic and Reconstructive Surgery Solutions
      • Surgical Solutions
      • Venous technology
  • Knowledge Center
    • Events
    • Literature
    • Training
  • Support
    • Customer Portals
      • Medication Management Customer Login
      • Customer Care Portal Guides and FAQ’s
      • My BD Learning
  • About BD
    • Our Company
      • About BD
      • Segments
      • Leadership
      • Board of Directors
      • Ethics and Compliance
    • BD IV Fluid Support
    • Cybersecurity at BD
      • About Us
      • Trust Center
      • Bulletins and Patches
      • Disclosure Process
      • Helpful Resources
    • Distributors
      • Distributor List
      • Unique device identifier (UDI)
    • Corporate Sustainability
      • Climate Change
      • Healthy Workforce & Communities
      • Product Impact
      • Supply Chain
      • Transparency
    • Global External Funding Opportunities
    • Investors
    • Innovation at BD
      • Overview
      • BD Idea Submission Process
    • News, Media and Blogs
    • Policies, Guidelines and Statements Center
    • Quality
    • Recent Mergers and Acquisitions
    • Suppliers
      • Corporate Policies and Expectations
      • Doing Business with BD
      • Global Procurement
      • Supplier Programs
      • Supplier Recognition
  • Careers
  • Country

    United States

    • North America
      • Canada (EN)
      • Canada (FR)
      • Mexico
      • United States
      South America
      • América Latina
      • Argentina
      • Chile
      • Colombia
      Europe
      • Belgique
      • België
      • Česká republika
      • Deutschland
      • España
      • Europe
      • France
      • ישראל
      • Italia
      • Nederland
      • Nordics
      • Österreich
      • Polska
      • Schweiz
      • United Kingdom
      Middle East, North Africa, Turkey
      • Middle East, North Africa, Turkey
      • South Africa
      Asia Pacific
      • Australia & New Zealand
      • 中国
      • Greater Asia
      • India
      • 日本
      • 대한민국
      • Southeast Asia
  • Login Here

    Login

  • Products
  • Solutions
    • Administrator
      • Ambulatory Surgery Center Solutions
      • BD Hypodermic Needle and Syringe Solutions
      • Diagnostic Accuracy and Efficiency
      • Hazardous Drug Safety
      • Integrated Diagnostic Solutions
      • Medication Management Solutions
      • Patient Safety Solutions
      • Sepsis Management
      • Surgical Solutions
      • Targeted Temperature Management
      • Vascular Access Management (VAM)
    • Clinician
      • Ambulatory Surgery Center Solutions
      • Antimicrobial Resistance
      • BD Original Equipment Manufacturing (OEM)
      • BD Hypodermic Needle and Syringe Solutions
      • Cervical Cancer Screening Portfolio
      • Clinical and Lab Support
      • Diagnostic Accuracy and Efficiency
      • Hazardous Drug Safety
      • Integrated Diagnostic Solutions
      • Medication Management Solutions
      • Patient Safety Solutions
      • Sepsis Management
      • Stone Management
      • Surgical Solutions
      • Targeted Temperature Management
      • Vascular Access Management (VAM)
    • Distributor
      • BD Original Equipment Manufacturing (OEM)
      • BD Hypodermic Needle and Syringe Solutions
    • Drug Development Company
      • Drug Delivery Systems
    • Medical Device Manufacturer
      • BD Original Equipment Manufacturing (OEM)
    • Laboratory
      • Antimicrobial Resistance
      • BD Original Equipment Manufacturing (OEM)
      • Cervical Cancer Screening Portfolio
      • Clinical and Lab Support
      • Clinical Microbiology
      • Diagnostic Accuracy and Efficiency
      • Integrated Diagnostic Solutions
      • Patient Safety Solutions
      • Pharmaceutical Microbiology
      • Sepsis Management
    • Pharmacy
      • BD Hypodermic Needle and Syringe Solutions
      • Hazardous Drug Safety
      • Integrated Diagnostic Solutions
      • Medication Management Solutions
      • Patient Safety Solutions
      • Pharmaceutical Microbiology
      • Sepsis Management
      • Vascular Access Management (VAM)
    • Surgery
      • Ambulatory Surgery Center Solutions
      • BD Hypodermic Needle and Syringe Solutions
      • Hernia Repair Solutions
      • Patient Safety Solutions
      • Plastic and Reconstructive Surgery Solutions
      • Surgical Solutions
      • Venous technology
  • Knowledge Center
    • Events
    • Literature
    • Training
  • Support
    • Customer Portals
      • Medication Management Customer Login
      • Customer Care Portal Guides and FAQ’s
      • My BD Learning
  • About BD
    • Our Company
      • About BD
      • Segments
      • Leadership
      • Board of Directors
      • Ethics and Compliance
    • BD IV Fluid Support
    • Cybersecurity at BD
      • About Us
      • Trust Center
      • Bulletins and Patches
      • Disclosure Process
      • Helpful Resources
    • Distributors
      • Distributor List
      • Unique device identifier (UDI)
    • Corporate Sustainability
      • Climate Change
      • Healthy Workforce & Communities
      • Product Impact
      • Supply Chain
      • Transparency
    • Global External Funding Opportunities
    • Investors
    • Innovation at BD
      • Overview
      • BD Idea Submission Process
    • News, Media and Blogs
    • Policies, Guidelines and Statements Center
    • Quality
    • Recent Mergers and Acquisitions
    • Suppliers
      • Corporate Policies and Expectations
      • Doing Business with BD
      • Global Procurement
      • Supplier Programs
      • Supplier Recognition
  • Careers
  • Country

    United States

    • North America
      • Canada (EN)
      • Canada (FR)
      • Mexico
      • United States
    • South America
      • América Latina
      • Argentina
      • Chile
      • Colombia
    • Europe
      • Belgique
      • België
      • Česká republika
      • Deutschland
      • España
      • Europe
      • France
      • ישראל
      • Italia
      • Nederland
      • Nordics
      • Österreich
      • Polska
      • Schweiz
      • United Kingdom
    • Middle East, North Africa, Turkey
      • Middle East, North Africa, Turkey
      • South Africa
    • Asia Pacific
      • Australia & New Zealand
      • 中国
      • Greater Asia
      • India
      • 日本
      • 대한민국
      • Southeast Asia
  • Login here Login

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • BD Innovates
    • Email Alerts
    • Other Notices
  • Company Info
    • Overview
    • Executive Leadership
    • Annual Reports and Proxy
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Credit Rating
    • Additional Financial Information
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
    • Stock Split History
    • Dividends
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Sustainability
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
    • Contact the Board
    • Reporting Accounting, Internal Accounting Controls or Auditing Matters
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • BD Innovates
  • Email Alerts
  • Other Notices
Aug 13, 2020 8:57 am EDT
BD to Present at UBS Genomics 2.0 and MedTech Innovations Virtual Summit
Aug 10, 2020 6:58 am EDT
BD and BD Foundation commit $7.8 million to helping community health centers expand innovative care to patients
Aug 6, 2020 6:00 am EDT
BD Announces Results For 2020 Third Fiscal Quarter; Provides Fiscal 2020 Guidance
Aug 3, 2020 6:58 am EDT
BD releases FY 2019 Sustainability Report
Jul 30, 2020 5:13 pm EDT
BD Announces $24 Million U.S. Government Investment to Support Scale Up of U.S. Manufacturing of COVID-19 Diagnosic Tests
Jul 27, 2020 4:10 pm EDT
BD Board Declares Dividends
Jul 22, 2020 6:59 am EDT
BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities
Jul 21, 2020 6:59 am EDT
BD Receives Additional Orders For 177 Million Injection Devices For U.S., Canada COVID-19 Vaccine Preparations
Jul 15, 2020 6:59 am EDT
BD Supports U.S. Government Efforts to Increase COVID-19 Testing Capacity with Point-of-Care Tests
Jul 8, 2020 6:59 am EDT
BD Partners with U.S. Government on $70 Million Manufacturing Infrastructure Project for Mass Vaccination Campaigns
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • Page 37
  • …
  • Page 89
  • Next Pagearrow_forward
rss_feed News RSS
By reading this content you are acknowledging our forward looking statement.

Forward Looking Statement

The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, newsletters and similar events and communications contains forward-looking statements (as defined under Federal securities laws) based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of BD may differ materially from those expressed or implied by such forward-looking statements and assumptions. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures.

All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company's control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.

  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
  • accessibilityAccessibility Statement
  • Follow us
    • Linked In
    • Facebook
    • Instagram
    • Twitter
    • Youtube
Quick Links
  • Recalls and Field Actions
  • Careers
  • Cybersecurity
  • Electronic Instructions for Use
  • Events
  • Investors
  • Inclusion, Diversity, Equity & Engagement
  • Literature
  • Live Chat Support
  • News, Media and Blogs
  • Our Company
  • Ethics and Compliance
  • Support
  • Training
Becton, Dickinson and Company

©2025 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners.

  • Contact us
  • Cookie Preferences
  • Privacy Statement
  • Terms of Use
  • Website Accessibility
  • Your Privacy Rights
  • Limit the use of Sensitive Personal Information